Platinum drugs: from Pt(II) compounds, Pt(IV) prodrugs, to Pt nanocrystals/nanoclusters

Hu, Xi; Li, Fangyuan; Noor, Nabila; Ling, Daishun

doi:10.1016/j.scib.2017.03.008

Cited by 52 publications

(31 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, based on the first-generation platinum drug cisplatin, the second-generation platinum chemotherapy drug carboplatin was developed, which took more than 10 years to reach the clinic. Compared with cisplatin, carboplatin exhibits a lower hydration rate due to the bidentate cyclobutane dicarboxylic acid ligands 32 , 33 and has high biosafety with greatly reduced systemic toxicity, including hepatotoxicity, nephrotoxicity, neurotoxicity, and ototoxicity 34 . Because of its lower toxicity, carboplatin can be used as high-dose chemotherapy for aggressive tumors.…”

Section: Development Of First-line Pt Drugsmentioning

confidence: 99%

Platinum-based drugs for cancer therapy and anti-tumor strategies

Zhang¹,

Xu²,

Gao³

et al. 2022

Theranostics

430

175

View full text Add to dashboard Cite

Platinum-based drugs cisplatin, carboplatin, and oxaliplatin are widely used for chemotherapeutic eradication of cancer. However, the side effects of platinum drugs, such as lack of selectivity, high systemic toxicity, and drug resistance, seriously limit their clinical application. With advancements in nanotechnology and chemical synthesis, Pt-based anti-cancer drugs have made great progress in cancer therapy in recent years. Many strategies relied on the anti-cancer mechanism similar to cisplatin and achieved some success by modifying existing platinum drugs. Pt-based nanodrugs, such as platinum nanoclusters, have novel anti-cancer mechanisms and great potential in tumor-targeted therapy and have shown promising results in clinical application. In this review, we systematically explored the development of first-line platinum chemotherapy drugs in the clinic and their anti-cancer mechanisms. We also summarize the progress of Pt-based anti-cancer drug application in cancer therapy, emphasizing their modification to enhance the anti-tumor effect. Finally, we address challenges faced by platinum chemotherapy drugs, especially Pt nanocluster-based nanodrugs, in cancer treatment. The new platinum drugs and their targeted modifications undoubtedly provide a promising prospect for improving the current anti-cancer treatments.

show abstract

Section: Development Of First-line Pt Drugsmentioning

confidence: 99%

Platinum-based drugs for cancer therapy and anti-tumor strategies

Zhang¹,

Xu²,

Gao³

et al. 2022

Theranostics

430

175

View full text Add to dashboard Cite

show abstract

“…As mentioned for chemotherapy, Pt(II)-based chemotherapeutics are traditional and preferred candidates for the clinical treatment of solid tumors [96]. After the approval of the Food and Drug Administration (FDA) in 1978, Pt chemotherapeutic drugs have evolved initially from cisplatin to carboplatin, lobaplatin and oxaliplatin [97,98].…”

Section: Chemotherapymentioning

confidence: 99%

Noble metal nanomaterials for the diagnosis and treatment of hematological malignancies

Huang¹,

Mahmudul²,

Li³

et al. 2022

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

Background:Recently, the incidence of hematological malignancy, such as various leukemias, multiple myeloma and lymphoma, has revealed an increasing tendency, exhibiting a major impact on human health. Most of the available anti-cancer drugs, however, possess high non-targeted accumulation, dosage-associated toxicity, fast elimination, and lack specificity towards tumors, which restrict their utilization in clinical therapy. This extends also to cancer diagnosis where there is a lack of predictive biomarkers. Object: Noble metal nanomaterials (NM NMs) have the potential to overcome these shortcomings due to several characteristics including ease of synthesis, ultra-small size, easy surface modification and specific physicochemical properties. At present, gold-, silver-and platinumbased nanomaterials have been employed in the tracing and treatment of hematopoietic tumors through direct individual endocytosis or in innovative drug delivery systems (DDS) by conjugation with other targeting biomolecules. Purpose: In this mini review, we focus on the use of localized surface plasmon resonance (LSPR)-/surface-enhanced Raman scattering (SERS)-and fluorescence-based diagnosis of NM NMs in the hematological malignancies. Furthermore, the treatment of hematological malignancies utilized the NM NMs or NM NMs-based therapy technology in the chemotherapy, targeted therapy, and photothermal therapy are depicted in depth. The construction of effective and promising NM NMs or NM NMs-dependent theranostic methodology has the potential to provide interdisciplinary knowledge in the development of clinical tracing, diagnosis and treatment of refractory hematological diseases.

show abstract

“…Notably, they can generate different contrast signals in monodispersed or aggregated states, which renders them ideal ingredients for image-enhancing DS [45]. Pt nanoparticles can exert anticancer activities by releasing bivalent Pt ions (Pt 2+ ) in the acidic environment [46], while gold nanoparticles (AuNPs) have characteristic surface plasma resonance properties applicable for colorimetric biosensing [47]. Moreover, upconversion and downconversion nanoparticles (UCNPs and DCNPs, respectively) are also commonly used for DS synthesis.…”

Section: Building Blocksmentioning

confidence: 99%